Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and first-generation somatostatin analogues (PAPE study).

Conclusions: Switching to PAS-LAR, either as monotherapy, or combination with pegvisomant, can control IGF-I levels in the majority of patients. PAS-LAR demonstrated a pegvisomant sparing effect of 66% compared to the combination with LA-SSAs. Hyperglycemia was the most important safety issue. PMID: 29155991 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research